Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer: 
A Case Report and Literature Review

Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer: 
A Case Report and Literature Review

Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induce...

Full description

Bibliographic Details
Main Authors: Jingjing CAI, Guangxia YANG, Xuemei ZHANG, Linlin LIU, Mei YAN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2023-09-01
Series:Chinese Journal of Lung Cancer
Subjects:
immune checkpoint inhibitors
sintilimab injection
immune thrombocytopenia
lung neoplasms
immune-related adverse events
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.32

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.32

Similar Items